EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Suzetrigine, a Non‐Opioid Small‐Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science

Rhea Rajasingham, Yanfei Qi iD

Clinical and Translational Science · 2025-11 · 18 (11)

DOI: 10.1111/cts.70414 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 18.11.2025. Verfasst von Rhea Rajasingham und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nasuti College of Osteopathic Medicine, Duquesne University, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Analgesics, Non-Narcotic, Analgesics. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery and approval of Suzetrigine (VX‐548, Journavx) marks a significant breakthrough in pain management. It is the first non‐opioid analgesic approved since celecoxib in 1998. Suzetrigine selectively blocks voltage‐gated sodium channel Na v 1.8 and acts exclusively on peripheral nociceptors without crossing the blood–brain barrier, providing analgesia while sparing central nervous system side effects such as dependence, addiction, sedation, and respiratory depression. In vitro experiments have demonstrated that Suzetrigine is a state‐dependent inhibitor with nanomolar potency against human Na v 1.8, exhibiting > 31,000‐fold selectivity compared to other subtypes of sodium channels and molecular targets. Suzetrigine is rapidly absorbed following oral administration with peak plasma concentrations ( T max ) in approximately 3 h under fasting conditions and an effective half‐life ( t 1/2 ) of 23.6 h. Suzetrigine is primarily eliminated via hepatic metabolism. Recent phase II and III clinical trials have validated Suzetrigine's efficacy in acute postoperative pain settings, demonstrating statistically significant reductions in pain intensity over 48 h following abdominoplasty and bunionectomy. Additionally, Suzetrigine has shown favorable safety and tolerability in broader acute pain indications and is under continued investigation for the treatment of chronic neuropathic conditions such as diabetic peripheral neuropathy. Pharmacokinetic and pharmacodynamic data support Suzetrigine's rapid oral absorption, state‐dependent Na v 1.8 inhibition, and limited off‐target activity as confirmed by both nonclinical and clinical safety studies. Suzetrigine received approval for use in January 2025 in the United States only. Ongoing trials are exploring novel formulations, long‐term safety, and integration into multimodal regimens for surgical and non‐surgical pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, Non-NarcoticAnalgesicsHumansTranslational Research, BiomedicalAnimalsNAV1.8 Voltage-Gated Sodium ChannelClinical Trials as TopicPain ManagementSpiro CompoundsThiophenes

Stichwörter der Autor:innen

Suzetriginepainvoltage‐gated sodium channel

Substanzen

((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineAnalgesics, Non-NarcoticNAV1.8 Voltage-Gated Sodium ChannelAnalgesicsSpiro CompoundsThiophenes

Autor:innen und Institutionen

  • Nasuti College of Osteopathic Medicine, Duquesne University, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Yanfei Qi

Zitieren

APA

Rajasingham, R., & Qi, Y. (2025). Suzetrigine, a Non‐Opioid Small‐Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science, 18(11). https://doi.org/10.1111/cts.70414

Vancouver

Rajasingham R, Qi Y. Suzetrigine, a Non‐Opioid Small‐Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. 2025;18(11). doi:10.1111/cts.70414

BibTeX
@article{Rajasingham2025,
  author = {Rajasingham, Rhea and Qi, Yanfei},
  title = {Suzetrigine, a Non‐Opioid Small‐Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {11},
  doi = {10.1111/cts.70414}
}
Kostenlos starten →